Article Abstract

Professor Shukui Qin: patient reported outcomes in study of axitinib or sorafenib in Asian patients with metastatic renal cell carcinoma

Authors: Shannon Zhang


Prof. Shukui Qin is the deputy director of People’s Liberation Army (PLA) 81 Hospital (Nanjing, China), director of Cancer Center of Chinese PLA, and director of National Drug Clinical Trial Agency of PLA 81 Hospital. He serves as the executive member of the Asian Clinical Oncology Society (ACOS), chair of Chinese Society of Clinical Oncology (CSCO), council member of PLA Medical Science Commission (and the executive member of its oncology society), member of the Oncology Branch of Chinese Medical Association.